Athira Pharma, Inc. (NASDAQ:LONA) Stock Has Average Price Target of $17.33

Athira Pharma, Inc. (NASDAQ:LONA) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $17.33.

Several research firms recently issued reports on LONA. Citizens Jmp dropped their price objective on Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating for the company in a research note on Monday, August 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Athira Pharma in a research report on Friday, August 7th. Wall Street Zen upgraded Athira Pharma to a “hold” rating in a research report on Saturday, October 17th. Finally, Mizuho decreased their target price on Athira Pharma from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 19th.

Athira Pharma Stock Down 1.7%

Shares of NASDAQ LONA opened at $4.76 on Friday. Athira Pharma has a 52 week low of $2.21 and a 52 week high of $14.21. The business has a 50-day simple moving average of $6.29 and a two-hundred day simple moving average of $7.60. The company has a market cap of $44.70 million, a P/E ratio of -1.13 and a beta of 2.11.

Athira Pharma (NASDAQ:LONA) last posted its earnings results on Friday, August 14th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.20). Equities research analysts anticipate that Athira Pharma will post -2.67 EPS for the current year.

Athira Pharma Company Profile

Athira Pharma is a clinical-stage biotechnology company focused on developing regenerative therapies for neurodegenerative diseases. Its research has centered on treatments intended to activate the hepatocyte growth factor pathway, which may support neuronal health, repair, and regeneration.

The company’s lead investigational product is fosgonimeton, formerly known as ATH-1017, an intravenous therapy developed for potential use in Alzheimer’s disease and other neurodegenerative conditions.